Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405785 | 1.00 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11154395 | 0.85 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL19469394 | 0.85 | LMNA (0.62) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL22028173 | 0.83 | LMNA (0.60) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL289057 | 0.82 | MEN1 (0.68) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL29541081 | 0.82 | MEN1 (0.63) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL10950131 | 0.82 | MEN1 (0.63) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL288893 | 0.82 | MEN1 (0.63) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3446901 | 0.81 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL609998 | 0.81 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | UNIVERSITY OF SOUTH CAROLINA | 2024-03-21 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| US-20230018537-A1 | PREDICTING AND ADDRESSING SEVERE DISEASE IN INDIVIDUALS WITH SEPSIS | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2023-01-19 | — | — | US | claimed |
| EP-4082028-A1 | PREDICTING AND ADDRESSING SEVERE DISEASE IN INDIVIDUALS WITH SEPSIS | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (US) | 2022-11-02 | — | — | EP | claimed |
| US-20220187315-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | DUKE UNIVERSITY | 2022-06-16 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220034893-A1 | Metabolomic Signatures for Predicting, Diagnosing, and Prognosing Various Diseases Including Cancer | Metabolomycs, Inc. (US) | 2022-02-03 | — | — | US | claimed |
| EP-3938528-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | Duke University (US) | 2022-01-19 | — | — | EP | claimed |
| US-11181525-B2 | Metabolomic signatures for predicting, diagnosing, and prognosing various diseases including cancer | Metabolomyes, Inc. (US) | 2021-11-23 | — | — | US | claimed |
| WO-2021134027-A1 | PREDICTING AND ADDRESSING SEVERE DISEASE IN INDIVIDUALS WITH SEPSIS | HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE (US) | 2021-07-01 | — | — | WO | claimed |
| EP-2492690-A1 | Method and use of metabolites for the diagnosis of inflammatory brain injury in preterm born infants | BIOCRATES Life Sciences AG (AT) | 2012-08-29 | — | — | EP | claimed |
| US-20120208282-A1 | Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. | BIOCRATES LIFE SCIENCES AG | 2012-08-16 | — | — | US | claimed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | claimed |
| CN-102473208-A | Method for normalization in metabolomics analysis methods using endogenous reference metabolites | BIOCRATES LIFE SCIENCES AG | 2012-05-23 | — | — | CN | claimed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | claimed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | claimed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | claimed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | claimed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | claimed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | NDUFAB1, OAT, CPT2 | MEN1 3476/4885KMT2A 2356/4885CYP1A2 783/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | MEN1 2449/4885KMT2A 1149/4885CYP1A2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.